Insights
Search Results
Client Highlights
7.10.25
Wilson Sonsini Advises Aqtual on $31 Million Series B
On July 10, 2025, Aqtual, a Hayward, California-based precision medicine company, announced the closing of its $31 million Series B financing round. Investors in the oversubscribed round included Bold Capital, the Bold Longevity Growth Fund, Genoa Ventures, Manta Ray Ventures, Yu Galaxy, and others. Wilson Sonsini Goodrich & Rosati advised Aqtual on the transaction.
Client Highlights
2.27.25
Wilson Sonsini Advises IonQ on Equity Offering Program for Up to $500 Million
On February 26, 2025, IonQ, a leader in the quantum computing and networking industries, announced that it has entered into an equity distribution agreement with Morgan Stanley & Co. and Needham & Company under which it may offer and sell shares of its common stock having an aggregate offering price of up to $500 million from time to time, pursuant to an “at-the-market” equity offering program. Wilson Sonsini Goodrich & Rosati is advising IonQ on the offering.
IonQ intends to use the net proceeds for general corporate purposes, which may include, among other things, acceleration of its networking business and the creation of new lines of growth in promising application areas.
The Wilson Sonsini team advising IonQ includes Mark Fitzgerald, Mark Bass, Roz Lynch, Erica Wolfe Heinz, and Taylor Miller.
IonQ intends to use the net proceeds for general corporate purposes, which may include, among other things, acceleration of its networking business and the creation of new lines of growth in promising application areas.
The Wilson Sonsini team advising IonQ includes Mark Fitzgerald, Mark Bass, Roz Lynch, Erica Wolfe Heinz, and Taylor Miller.
Client Highlights
11.19.24
Wilson Sonsini Advises Investors on Zenflow’s $24 Million Series C Financing
On November 18, 2024, Zenflow, Inc., a medical device company developing a minimally invasive treatment for urinary obstruction caused by enlarged prostate, or benign prostatic hyperplasia (BPH), announced that it has closed a $24 million Series C financing round. The round included new investor Cook Medical as well as existing investors Invus Opportunities, F-Prime Capital, Medical Technology Venture Partners, and others. Wilson Sonsini Goodrich & Rosati advised Invus, F-Prime, and MedTech Venture Partners on the transaction.
The proceeds from the financing will be used to support Zenflow’s Pre-Market Approval (PMA) submission and prepare for commercialization upon FDA approval of its Spring® System, a minimally invasive treatment option for patients who suffer debilitating symptoms due to enlarged prostate.
The Wilson Sonsini team that advised Invus, F-Prime, and MedTech Venture Partners on the transaction included Jen Fang and Taylor Miller.
For more information, please see Zenflow’s news release.
The proceeds from the financing will be used to support Zenflow’s Pre-Market Approval (PMA) submission and prepare for commercialization upon FDA approval of its Spring® System, a minimally invasive treatment option for patients who suffer debilitating symptoms due to enlarged prostate.
The Wilson Sonsini team that advised Invus, F-Prime, and MedTech Venture Partners on the transaction included Jen Fang and Taylor Miller.
For more information, please see Zenflow’s news release.